Last year, the FDA published over 200 Complete Response Letters. The pattern was clear: most cell therapy rejections stem from CMC, comparability, and manufacturing readiness. Meanwhile, the number cell therapies in the clinic has increased by 13% from 2024 to 2025. This has led to growing pressures to move programs toward the next clinical stage and commercialization.

The science is working, but the processes need to catch up.

That's why the 5th Process Development & Automation for Cell Therapies Summit returns in 2026 - this time in San Diego.

Bringing together Process Development, Analytical Development, QC, and MSAT leaders from early clinical to commercial stage, this is the only industry-led event dedicated exclusively to the process development and automation challenges determining whether your therapy reaches patients.

View the event here.